Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period ActivityBusiness Wire • 05/04/23
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care ConferenceBusiness Wire • 05/03/23
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid AngiopathyBusiness Wire • 04/26/23
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 04/20/23
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial ResultsBusiness Wire • 04/20/23
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi TherapeuticsPRNewsWire • 03/09/23
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/23/23
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period ActivityBusiness Wire • 02/23/23
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR AmyloidosisBusiness Wire • 02/21/23
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial ResultsBusiness Wire • 02/02/23
Alnylam Pharmaceuticals Starts 2023 With In-Line Revenue And A Full Slate Of Clinical Read-OutsSeeking Alpha • 01/10/23
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional UpdatesBusiness Wire • 01/08/23
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/23